Bristol-Myers Squibb (BMY) Granted EC Approval for Inrebic (fedratinib) for Adult Patients with Newly Diagnosed & Previously Treated Myelofibrosis
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- SpaceX extends losses after $600 billion wipeout, tech stocks slide again
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
FDA Approves Bristol-Myers Squibb's (BMY) New Treatment For Adults With Relapsed Or Refractory Large-B-Cell Lymphoma
February 5, 2021 3:05 PM EST(Updated - February 5, 2021 3:06 PM EST)
Today, the U.S. Food and Drug Administration approved Breyanzi (lisocabtagene maraleucel), a cell-based gene therapy to treat adult patients with certain types of large B-cell lymphoma who have not responded to, or who have relapsed after, at least two other types of systemic treatment. Breyanzi, a chimeric antigen receptor (CAR) T cell therapy, is the third gene therapy approved by the FDA for certain types of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma (DLBCL). Breyanzi is not indicated for the treatment of patients with primary central nervous system lymphoma.
"Today's approval represents... More
Bristol-Myers Squibb Co. (BMY) PT Raised to $66 at Truist Securities
February 5, 2021 8:43 AM ESTTruist Securities raised its price target on Bristol-Myers Squibb Co. (NYSE: BMY) to $66.00 (from $65.00) while maintaining a Hold rating.... More
Bristol-Myers Squibb (BMY) Tops Q4 EPS by 5c, Offers FY Guidance
February 4, 2021 7:01 AM ESTBristol-Myers Squibb (NYSE: BMY) reported Q4 EPS of $1.46, $0.05 better than the analyst estimate of $1.41. Revenue for the quarter came in at $11.07 billion versus the consensus estimate of $10.73 billion.
GUIDANCE:
Bristol-Myers Squibb sees FY2021 EPS of $7.35-$7.55, versus the consensus... More
